Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MPO | P05164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7452613 | 0.78 | — | — | |
| SCHEMBL7456782 | 0.78 | — | — | |
| SCHEMBL545834 | 0.78 | MPO (0.33) | MPO | |
| SCHEMBL2634659 | 0.63 | — | — | |
| SCHEMBL1251785 | 0.59 | — | — | |
| SCHEMBL4062710 | 0.59 | — | — | |
| SCHEMBL73936 | 0.58 | — | — | |
| SCHEMBL3801963 | 0.57 | MPO (0.36) | MPO | |
| SCHEMBL7617975 | 0.57 | MPO (0.36) | MPO | |
| SCHEMBL6256754 | 0.54 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2023-03-07 | — | — | US | claimed |
| US-9884886-B2 | Disulfide masked prodrug compositions and methods | MERCK SHARP & DOHME (US) | 2018-02-06 | — | — | US | claimed |
| US-9192621-B2 | Esters and malonates of SATE prodrugs | IDENIX PHARMACEUTICALS LLC (US) | 2015-11-24 | — | — | US | claimed |
| WO-2015095305-A1 | PRODUCTION OF CYCLIC PHOSPHATE, PHOSPHORAMIDATE, THIOPHOSPHATE, AND PHOSPHONATE NUCLEOSIDE COMPOUNDS | IDENIX PHARMACEUTICALS, INC. (US) | 2015-06-25 | — | — | WO | claimed |
| US-8076310-B2 | Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production | K.U.LEUVEN RESEARCH & DEVELOPMENT (BE) | 2011-12-13 | — | — | US | claimed |
| US-20110009606-A1 | Synthesis of 2',3' - and 3',5' -cyclic phosphate mono-and oligonucleotides | CHEMGENES CORPORATION | 2011-01-13 | — | — | US | claimed |
| WO-2009120358-A1 | OLIGOMER-NITROGENOUS BASE CONJUGATES | NEKTAR THERAPEUTICS (US) | 2009-10-01 | — | — | WO | claimed |
| EP-1212339-B1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2008-12-31 | — | — | EP | claimed |
| US-20070179100-A1 | Protected monomers | ALNYLAM PHARMACEUTICALS, INC. | 2007-08-02 | — | — | US | claimed |
| EP-1625138-A2 | PROTECTED MONOMERS | Alnylam Pharmaceuticals Inc. (US) | 2006-02-15 | — | — | EP | claimed |
| EP-1212339-A4 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS INC (US) | 2002-09-18 | — | — | EP | claimed |
| EP-1212339-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2002-06-12 | — | — | EP | claimed |
| US-6271358-B1 | FOR INHIBITING SPECIFIC GENE EXPRESSION; HAVING ENHANCED HYBRID BINDING AFFINITY AND/OR INCREASED NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS, INC. | 2001-08-07 | — | — | US | claimed |
| WO-2001014400-A1 | 2'-O-ACETAMIDO MODIFIED MONOMERS AND OLIGOMERS | ISIS PHARMACEUTICALS, INC. (US) | 2001-03-01 | — | — | WO | claimed |
| US-6172209-B1 | MOLECULAR HYBRIDIZATION, GENETIC ENGINEERING; NUCLEASE RESISTANCE | ISIS PHARMACEUTICALS INC. | 2001-01-09 | — | — | US | claimed |
| US-6147200-A | NUCLEOSIDES FOR SOLID PHASE SYNTHESIS OF OLIGONUCLEOTIDES HAVING INCREASED NUCLEASE RESISTANCE AND BETTER BINDING AFFINITY; DIAGNOSIS; ANTISENSE THERAPY | ISIS PHARMACEUTICALS, INC. (US) | 2000-11-14 | — | — | US | claimed |
| US-6127533-A | SPECIFICALLY HYBRIDIZABLE WITH A SELECTED SEQUENCE OF RNA OR DNA; DIAGNOSIS OF DISEASES | ISIS PHARMACEUTICALS, INC. (US) | 2000-10-03 | — | — | US | claimed |
| US-5663159-A | VIRICIDES | INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) | 1997-09-02 | — | — | US | claimed |
| EP-0719274-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1996-07-03 | — | — | EP | claimed |
| WO-1995007919-A1 | METHOD FOR DOSING THERAPEUTIC COMPOUNDS | GILEAD SCIENCES, INC. (US) | 1995-03-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110009606-A1 | Synthesis of 2',3' - and 3',5' -cyclic phosphate mono-and oligonucleotides | ITPA, NT5C2, NT5C3B | MPO 3331/4885 |
| US-11597745-B2 | β-modified phosphoric acid compound precursor, β-modified phosphoric acid compound, reaction inhibitor and medicine containing the same, and method for inhibiting reaction | PPM1A, PPM1G, PPM1F | MPO 4679/4885 |
| US-20070179100-A1 | Protected monomers | PCNA, POLN, PARP1 | MPO 1234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.